IMRX Logo

Immuneering Corporation (IMRX) 

NASDAQ
Market Cap
$56.34M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
145 of 776
Rank in Industry
91 of 433

Largest Insider Buys in Sector

IMRX Stock Price History Chart

IMRX Stock Performance

About Immuneering Corporation

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. …

Insider Activity of Immuneering Corporation

Over the last 12 months, insiders at Immuneering Corporation have bought $477,955 and sold $3.91M worth of Immuneering Corporation stock.

On average, over the past 5 years, insiders at Immuneering Corporation have bought $6.25M and sold $3.91M worth of stock each year.

Highest buying activity among insiders over the last 12 months: BERMAN ANN E (director) — $246,873. Feinberg Peter (director) — $246,771. Zeskind Benjamin J. (PRESIDENT AND CEO) — $55,326.

The last purchase of 25,000 shares for transaction amount of $63,713 was made by Feinberg Peter (director) on 2024‑03‑22.

List of Insider Buy and Sell Transactions, Immuneering Corporation

2024-04-01Sale10 percent owner
400,000
1.4407%
$2.90$1.16M-44.18%
2024-03-22Purchasedirector
25,000
0.0853%
$2.55$63,713-39.61%
2024-03-22PurchaseChief Accounting Officer
393
0.0013%
$2.55$1,000-39.61%
2024-03-22PurchaseChief Business Officer
3,900
0.0134%
$2.57$10,015-39.61%
2024-03-22Purchasedirector
2,900
0.0099%
$2.55$7,385-39.61%
2024-03-21PurchaseChief Accounting Officer
1,107
0.0038%
$2.72$3,009-43.80%
2024-03-20PurchaseCHIEF SCIENTIFIC OFFICER
7,000
0.0246%
$2.86$20,020-44.60%
2024-03-20PurchaseCHIEF PEOPLE OFFICER
3,818
0.0135%
$2.88$10,993-44.60%
2024-03-19PurchasePRESIDENT AND CEO
20,000
0.0735%
$2.77$55,326-39.84%
2024-03-19Purchasedirector
25,000
0.085%
$2.56$64,000-39.84%
2024-03-18Purchasedirector
57,965
0.1647%
$2.13$123,436-39.84%
2024-03-18Purchasedirector
50,000
0.1588%
$2.38$119,058-39.84%
2024-03-15Sale10 percent owner
400,000
1.5312%
$2.14$856,400-18.85%
2024-03-14Sale10 percent owner
509,091
1.0954%
$3.72$1.89M-46.21%
2022-05-25PurchaseCHIEF SCIENTIFIC OFFICER
2,551
0.0097%
$3.92$10,000+74.81%
2022-05-17PurchaseGENERAL COUNSEL AND SECRETARY
1,000
0.0037%
$4.88$4,880+32.61%
2022-05-16Purchase
7,000
0.0283%
$5.00$35,000+42.64%
2022-05-12PurchaseCFO, TREASURER
1,000
0.0033%
$4.42$4,420+31.29%
2022-03-23PurchasePRESIDENT AND CEO
3,000
0.0119%
$8.02$24,060-18.85%
2022-03-23PurchaseCHIEF SCIENTIFIC OFFICER
1,050
0.0041%
$7.91$8,306-18.85%

Insider Historical Profitability

<0.0001%
Cormorant Asset Management, LP10 percent owner
2895273
9.7637%
$1.9013<0.0001%
Zeskind Benjamin J.PRESIDENT AND CEO
2281852
7.6951%
$1.9040<0.0001%
Hall Brett MatthewCHIEF SCIENTIFIC OFFICER
345896
1.1665%
$1.9040+2.71%
Feinberg Peterdirector
111766
0.3769%
$1.9070<0.0001%
BERMAN ANN Edirector
67465
0.2275%
$1.9030<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Cormorant Asset Management Lp$9.52M11.113.3M-21.62%-$2.63M0.44
Citadel Advisors LLC$5.44M6.351.88M-9.43%-$566,127.88<0.01
BlackRock$3.98M4.641.38M-34.34%-$2.08M<0.0001
The Vanguard Group$3.48M4.061.2M+12.09%+$375,269.42<0.0001
T. Rowe Price$2.63M3.07910,266-73.05%-$7.14M<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.